It is worth noting that the increased phytosterol in cases of elevated HDL-C elicited by the CETP inhibitor Dalcetrapib was similar to that seen with statin treatment (32), and different from that measured in ABCG5/G8 mutation leading to atherogenic phytosterolemia (33). This evidence concerns the gene ABCG5 and sitosterolemia.